Featured Products


Unprecedented, comprehensive cancer profiling

Simultaneous profiling of cell-free DNA and RNA

Predicine’s proprietary GeneRADAR next generation liquid biopsy platform measures cancer-associated genomic blueprint (DNA) and functional biology (RNA) in a single tube of blood to provide more accurate and in-depth insights.

Urine-based Liquid biopsy

Urine: Painless cancer detection

Fast, easy, and truly non-invasive.

Predicine introduces urine-based liquid biopsy to broaden cancer patients’ access to genomic profiling. Urine-based cfDNA can be more robust in variant detection than blood-based cfDNA in genitourinary cancers. 

Our assays and services

Predicine cfDNA assays for cancer monitoring

Molecular profiling assays

Predicine provides clinical services

Biopharma clinical research services

Predicine CDx Co-development

Co-development services



“Liquid biopsy is the future of precision medicine. Our work with Predicine’s liquid biopsy platform is very encouraging for the field of liquid biopsy and supports its clinical application for patient care.”

Massimo Cristofanilli, M.D.
Professor of Northwestern University and President of International Society of Liquid Biopsy


Unified biomarker solutions for global clinical trials

End-to-end clinical lab solutions in US and China from discovery to CDx

Through our network of CLIA/CAP certified facilities in California and Shanghai, Predicine partners with leading biopharmaceutical companies to support biomarker-driven clinical trials.

Get in touch

Ready to streamline your precision oncology clinical research programs? Submit your info via the form below and we will respond within 24 hours.